Écrit par EMBO | 12 Février 2013

HEIDELBERG, 12 February 2013 – How do you compare the impact of a researcher in chemistry or physics with a molecular biologist who may be working on similar projects? In an article published today in EMBO reports two experts support the use of citation indicators that are based on percentiles, a statistical parameter that allows for comparisons with a carefully defined group of reference...

Écrit par GBI Research | 05 Février 2013

India is the second diabetes capital of the world after China, with the treatment market growing at a double-digit year-on-year growth rate, presenting both domestic and Multinational Companies (MNCs) with promising opportunities, states a new report by healthcare experts GBI Research.

Diabetes represents a group of metabolic diseases, characterized by hyperglycemia resulting from...

Écrit par EMBO Journal | 05 Février 2013

5 February 2013 – EMBO and the Federation of European Biochemical Societies (FEBS) announce Geneviève Almouzni, deputy director of the Institut Curie in Paris, France, as the winner of the 2013 FEBS | EMBO Women in Science Award.

Professor Almouzni has been recognized for her outstanding contributions to research in the area of histones and chromatin, her engagement in promoting...

Écrit par novozymes | 31 Janvier 2013

Novozymes acquires Iogen Bio-Products, industrial enzyme business of Ottawa-based Iogen Corporation for CAD 67.5 million (approximately DKK 370 million) and potential earn-out payments of up to CAD 12.5 million (approximately DKK 70 million). The deal provides Novozymes with all commercial rights to Iogen Bio-Products’ existing product portfolio, pipeline, facilities and know-how...